Rexahn Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is dedicated to the discovery, development, and commercialization of treatments for cancer. Its mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn has developed three clinical-stage drug candidates: RX-3117, Supinoxin (RX-5902) and Archexin. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action.
| Website: | www.rexahn.com |
| Email: | info@rexahn.com |
| Main Phone: | +1 240 268-5300 |
| Address: | 15245 Shady Grove Road |
| Address 2: | Suite 455 |
| State: | MD |
| City / Town: | Rockville |
| Country: | USA |
| Postal Code: | 20850 |
| Exchange: | AMX |
| CEO: | Douglas J. Swirsky |
| Employees: | 10 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait Rexahn Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is dedicated to the discovery, development, and commercialization of treatments for cancer. Its mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn has developed three clinical-stage drug candidates: RX-3117, Supinoxin (RX-5902) and Archexin. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action.
| Website: | www.rexahn.com |
| Email: | info@rexahn.com |
| Main Phone: | +1 240 268-5300 |
| Address: | 15245 Shady Grove Road |
| Address 2: | Suite 455 |
| State: | MD |
| City / Town: | Rockville |
| Country: | USA |
| Postal Code: | 20850 |
| Exchange: | AMX |
| CEO: | Douglas J. Swirsky |
| Employees: | 10 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 4.92 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid 3.55 | Bid Size 100.00 | Ask 5.71 | Ask Size 1,000.00 |
| Open N/A | High N/A | Low N/A | Prev Close 4.92 |
| Last Trade | Volume 0 | 52 Wk Hi 28.56 | 52 Wk Low 4.71 |
| Market Cap 19.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 4,019,141.00 | EPS (TTM) -5.18 | PE Ratio N/A | Exchange NYSE American |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 4 |
| Number of Buys | 0 | 4 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 20250 |
| Last 10 Buys | Shares |
|---|---|
| Richard Kivel | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Chang Ho Ahn | 1,000 |
| Chang Ho Ahn | 1,000 |
| Tae Heum Jeong | 1,000 |
| Chang Ho Ahn | 1,000 |
| Tae Heum Jeong | 1,000 |
| Chang Ho Ahn | 1,000 |
| Tae Heum Jeong | 1,000 |
| Chang Ho Ahn | 1,000 |
| Tae Heum Jeong | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 19.5 | 19.5 | 19.5 | 19.5 |
| Low Target Price Estimate | 13 | 13 | 13 | 13 |
| Mean Target Price Estimate | 16.25 | 16.25 | 16.25 | 16.25 |
| Standard Deviation | 4.6 | 4.6 | 4.6 | 4.6 |
| Date of Most Recent Estimate | 03/12/18 | 03/12/18 | 03/12/18 | 03/12/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| DEFA14A | Additional proxy soliciting materials - definitive | 4 | 2018-06-14 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 40 | 2018-05-04 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 46 | 2018-04-23 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-18 |
| PRE 14A | Preliminary proxy statement providing notification matters to be brought to a vote | 46 | 2018-04-06 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-09 |
| 10-K | Annual report with a comprehensive overview of the company | 119 | 2018-03-09 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-02 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-02 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-02 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.33 | 1.33 | 1.33 | 1.33 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
